Upregulated Fibulin-1 Increased Endometrial Stromal Cell Viability and Migration by Repressing EFEMP1-Dependent Ferroptosis in Endometriosis

Figure 2

FBLN1 increased ESC viability and facilitated ESC migration. (a) Normal ESCs (NESCs) were treated with pcDNA-FBLN1 (or pcDNA control) for 48 h, and then, qPCR and western blot analysis were carried out to assess the FBLN1 protein expression in NESCs. After FBLN1 overexpression in NESCs, (b) CCK-8 assay and (c) FDA staining were carried out to assess cell viability. (d) Ectopic ESCs (EESCs) were treated with siFBLN1 (or negative control (N.C)) for 48 h, and then, qPCR and western blot analysis were carried out to assess the FBLN1 protein expression in EESCs. After FBLN1 silencing in EESCs, (e) CCK-8 assay and (f) FDA staining were carried out to assess cell viability. (g) After FBLN1 overexpression in NESCs, transwell migration assay was carried out to assess NESC migration. Scan . Magnification ×20. (h) After FBLN1 silencing in EESCs, transwell migration assay was carried out to assess NESC migration. Scan . Magnification ×20. (i) EESCs were treated with ZVAD-FMK (10 μM), necrostatin-1 (10 μM), and ferrostatin-1 (1 μM) in the presence or absence of siFBLN1, and then, CCK-8 assay was carried out to assess EESC viability. (j) EESCs were treated with ZVAD-FMK (10 μM), necrostatin-1 (10 μM), and ferrostatin-1 (1 μM) in the presence or absence of sorafenib, and then, CCK-8 assay was carried out to assess EESC viability. (k) EESCs were treated with erastin (10 μM) in the presence or absence of FBLN1 overexpression, and then, CCK-8 assay was carried out to assess EESC viability. and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)